Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704386 | PMC |
| http://dx.doi.org/10.3389/fendo.2021.797969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Will personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) or split-course SBRT based on systemic therapy (3S) be future directions in the Field of SBRT?
Int Immunopharmacol
December 2024
Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China; Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Fuzhou, Fujian, China; Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), Fuzhou, Fujian, China. Electronic address:
The combined use of stereotactic body radiotherapy (SBRT) and immunotherapy is a promising new development. However, the optimal modality for combining SBRT with immunotherapy needs further study. Timmerman and colleagues reported that the time split between radiotherapy and α-PD-L1 therapy can affect the therapeutic effect and introduced a new SBRT paradigm-personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR).
View Article and Find Full Text PDFExpert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
Biosci Trends
December 2024
Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center of the Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of the Chinese PLA, Beijing, China.
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits.
View Article and Find Full Text PDFClinical feasibility of Ethos auto-segmentation for adaptive whole-breast cancer treatment.
Front Oncol
December 2024
Radiotherapy Department, Montpellier Regional Cancer Institute, Montpellier, France.
Introduction: Following a preliminary work validating the technological feasibility of an adaptive workflow with Ethos for whole-breast cancer, this study aims to clinically evaluate the automatic segmentation generated by Ethos.
Material And Methods: Twenty patients initially treated on a TrueBeam accelerator for different breast cancer indications (right/left, lumpectomy/mastectomy) were replanned using the Ethos emulator. The adaptive workflow was performed using 5 randomly selected extended CBCTs per patient.
Comment on the Article: Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin II receptor blockers: a retrospective cohort study using LIFE Study data.
Hypertens Res
December 2024
Department of General Practice, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
Radiation-induced injury in endovascular surgery: How long is too long?
J Vasc Surg Cases Innov Tech
February 2025
Department of Vascular Surgery, Marshfield Clinic, Marshfield, WI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!